New drugs for the functional cure of hepatitis B： Focusing on antisense oligonucleotides and small interfering RNAs
Journal Title: Journal of Clinical Hepatology - Year 2025, Vol 41, Issue 1
Abstract
Existing nucleos（t）ide analogues and pegylated interferon exhibit limited efficacy in the functional cure of hepatitis B. Recently， small nucleic acid drugs， such as antisense oligonucleotides and small interfering RNAs， have brought unprecedented breakthroughs in the functional cure of hepatitis B with their brand-new mechanisms of action and remarkable efficacy in early clinical studies. Small nucleic acid drugs， such as antisense oligonucleotides and small interfering RNAs， can reduce the level of HBsAg and strive to achieve HBsAg seroclearance. The reduction in HBsAg may restore the hepatitis B-specific immune function of the body to some extent and may further transform the simple clearance of HBsAg into hard endpoints with clinical value， such as reducing hepatitis B-related liver events. By meticulously analyzing the dynamic trajectory of HBsAg alterations within the context of new drug applications and further optimizing combined treatment strategies and regimens， it is expected to transform the functional cure of hepatitis B into the ultimate goal of improving survival rates and quality of life.
Authors and Affiliations
Xieer LIANG, Zhihong LIU, Jinlin HOU
Keywords
Related Articles
- EP ID EP768551
- DOI 10.12449/JCH250102
- Views 6
- Downloads 0
Expression of CXCL10 and CXCL12 in gallbladder carcinoma and their mechanism of action in tumor invasion
[Objective] To investigate the expression levels of CXCL10 and CXCL12 in gallbladder carcinoma and their mechanism of action in tumor invasion. [Methods] Tumor tissue samples and adjacent tissue samples were collected fr...
Role of peripheral clock genes in the progression， prevention， and treatment of nonalcoholic steatohepatitis
As a severe clinical manifestation of nonalcoholic fatty liver disease， nonalcoholic steatohepatitis （NASH） is characterized by lipid deposition and inflammatory damage in the liver. At present， clinical medications...
Expert consensus on precision detection of intrahepatic cholangiocarcinoma （2024 edition）
Intrahepatic cholangiocarcinoma （ICC） is a highly heterogeneous tumor， and molecular profiling serves as the foundation for personalized treatment of ICC. Accurate detection methods are clinically significant for comp...
An excerpt of EASL clinical practice guidelines on liver transplantation （2024 edition）
In July 2024， the European Association for the Study of the Liver released the latest edition of EASL Clinical Practice Guidelines on liver transplantation. The purpose of the EASL guidelines presented here is not to co...
Molecular mechanism of lenvatinib resistance in hepatocellular carcinoma
Hepatocellular carcinoma is the most common malignancy of the liver and poses serious health burdens on China and the whole world. However， most patients with hepatocellular carcinoma are already in the advanced stage a...